At 54 weeks in the STOP-HS1 and STOP-HS2 trials, up to 71.4% of patients taking povorcitinib achieved at least a 50% reduction from baseline in the total abscess and inflammatory ...

Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. HS, a chronic, recurrent ...

Eltanany, M. , Matar, R. and Elrashidy, A. (2026) Management of Periurethral Abscess in a Diabetic 47-Year-Old Male: A Case ...

How can patients tell when tooth pain has become serious enough to require a root canal? That question is answered in a HelloNation article featuring Dr. Allen Meier of the Endodontic Center of ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...

London curator Ekow Eshun shares his vision for the 2027 SITE Santa Fe International Biennial ...

Sonelokimab is a member of a novel biologic class known as a nanobody. In contrast to a conventional monoclonal antibody, a ...

Bimekizumab at different dosing intervals was associated with greater IHS4 improvements at week 48 than placebo in patients with HS.

Povorcitinib, an oral JAK-1 inhibitor currently being investigated for hidradenitis suppurativa, demonstrated substantial clinical efficacy through 54 weeks, according to new data. Patients with ...

Different doses lead to different effects on the body and the brain ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the ...